Celcuity (NASDAQ:CELC) Trading Up 6% – Should You Buy?

Celcuity, Inc. (NASDAQ:CELC) shares were up 6% during mid-day trading on Monday . The stock traded as high as $126.67 and last traded at $128.2430. Approximately 179,503 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 724,566 shares. The stock had previously closed at $121.03.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CELC shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $122.00 price target on shares of Celcuity in a research report on Thursday, March 26th. Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday. Stifel Nicolaus lifted their price target on Celcuity from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research report on Monday, April 20th. Finally, Citizens Jmp started coverage on Celcuity in a research report on Monday. They issued a “market outperform” rating and a $150.00 price target for the company. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Celcuity currently has an average rating of “Moderate Buy” and a consensus price target of $114.33.

Celcuity Trading Down 4.5%

The stock has a 50-day simple moving average of $113.98 and a two-hundred day simple moving average of $101.61. The company has a debt-to-equity ratio of 3.20, a quick ratio of 10.55 and a current ratio of 10.55. The firm has a market cap of $5.80 billion, a PE ratio of -31.68 and a beta of 0.41.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.09. As a group, sell-side analysts anticipate that Celcuity, Inc. will post -3.97 EPS for the current year.

Insiders Place Their Bets

In other Celcuity news, Director Richard E. Buller sold 3,000 shares of the business’s stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $110.27, for a total value of $330,810.00. Following the completion of the transaction, the director owned 6,760 shares of the company’s stock, valued at approximately $745,425.20. The trade was a 30.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.33% of the company’s stock.

Hedge Funds Weigh In On Celcuity

A number of hedge funds have recently bought and sold shares of the business. Abel Hall LLC purchased a new position in Celcuity in the 1st quarter worth about $236,000. Pictet Asset Management Holding SA bought a new stake in shares of Celcuity during the 1st quarter valued at about $358,000. Hsbc Holdings PLC bought a new stake in shares of Celcuity during the 4th quarter valued at about $1,058,000. Seven Fleet Capital Management LP bought a new stake in shares of Celcuity during the 4th quarter valued at about $783,000. Finally, Invesco Ltd. grew its stake in shares of Celcuity by 4.9% during the 4th quarter. Invesco Ltd. now owns 147,938 shares of the company’s stock valued at $14,755,000 after purchasing an additional 6,928 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.